
A groundbreaking review highlights the transformative potential of Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i) beyond diabetes treatment, particularly in cardiovascular disease (CVD). These drugs not only alleviate CVD symptoms but also benefit patients with nonalcoholic fatty liver disease and chronic kidney disease by reducing liver fat, improving kidney function, and mitigating heart failure risks. Their efficacy extends to reducing hospitalizations and mortality risks in various cardiac conditions. SGLT2 inhibitors emerge as versatile metabolic drugs, offering hope for comprehensive management of heart failure, diabetes, and kidney disease, embodying values of holistic patient care and medical innovation.
Like
Save
Share